SK63998A3 - Quinoline derivatives, method for the preparation thereof, pharmaceutical composition containing same, and their use - Google Patents

Quinoline derivatives, method for the preparation thereof, pharmaceutical composition containing same, and their use Download PDF

Info

Publication number: SK63998A3
Authority: SK; Slovakia
Prior art keywords: benzo; methyl; quinoline; thiadiazolyl; triazolyl
Prior art date: 1995-11-14

Application number

SK639-98A

Other languages

English (en)

Slovak (sk)

Inventor

Rainer Luond

Villar E Pombo

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-14

Filing date

1996-11-13

Publication date

1998-10-07

1996-11-13 Application filed by Novartis Ag filed Critical Novartis Ag

1998-10-07 Publication of SK63998A3 publication Critical patent/SK63998A3/sk

Links

238000000034 method Methods 0.000 title claims abstract description 27
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
238000002360 preparation method Methods 0.000 title claims description 10
229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title description 4
125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
-1 benzo[c]furazanyl Chemical group 0.000 claims abstract description 59
238000011282 treatment Methods 0.000 claims abstract description 53
125000001113 thiadiazolyl group Chemical group 0.000 claims abstract description 25
239000002253 acid Substances 0.000 claims abstract description 19
239000003814 drug Substances 0.000 claims abstract description 17
150000003863 ammonium salts Chemical group 0.000 claims abstract description 15
150000001204 N-oxides Chemical class 0.000 claims abstract description 14
125000004076 pyridyl group Chemical group 0.000 claims abstract description 7
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 6
230000008569 process Effects 0.000 claims abstract description 6
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 40
125000005605 benzo group Chemical group 0.000 claims description 29
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
201000010099 disease Diseases 0.000 claims description 22
150000003839 salts Chemical class 0.000 claims description 21
230000002757 inflammatory effect Effects 0.000 claims description 15
230000000414 obstructive effect Effects 0.000 claims description 11
125000000217 alkyl group Chemical group 0.000 claims description 10
208000027866 inflammatory disease Diseases 0.000 claims description 9
208000023275 Autoimmune disease Diseases 0.000 claims description 7
208000024827 Alzheimer disease Diseases 0.000 claims description 6
208000018737 Parkinson disease Diseases 0.000 claims description 6
125000004432 carbon atom Chemical group C* 0.000 claims description 6
239000003085 diluting agent Substances 0.000 claims description 6
VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims description 5
208000006011 Stroke Diseases 0.000 claims description 4
229910052760 oxygen Inorganic materials 0.000 claims description 4
229910052717 sulfur Inorganic materials 0.000 claims description 4
125000001425 triazolyl group Chemical group 0.000 claims description 4
QJKXVPWAXPWTSO-UHFFFAOYSA-N 8-(2-methylbenzotriazol-5-yl)-6-(pyridin-4-ylmethyl)quinoline Chemical compound C=1C2=NN(C)N=C2C=CC=1C(C1=NC=CC=C1C=1)=CC=1CC1=CC=NC=C1 QJKXVPWAXPWTSO-UHFFFAOYSA-N 0.000 claims description 3
KODGCUXGWQLAEK-UHFFFAOYSA-N 3-[6-(pyridin-4-ylmethyl)quinolin-8-yl]-1h-2,1,3-benzoxadiazole Chemical compound C=1C(N2C3=CC=CC=C3NO2)=C2N=CC=CC2=CC=1CC1=CC=NC=C1 KODGCUXGWQLAEK-UHFFFAOYSA-N 0.000 claims description 2
229910052799 carbon Inorganic materials 0.000 claims description 2
JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 claims description 2
150000003852 triazoles Chemical class 0.000 claims description 2
DRQNHAXZLIONQV-UHFFFAOYSA-N 4-(6-pyridin-4-ylquinolin-8-yl)-2,1,3-benzoxadiazole Chemical compound C12=NON=C2C=CC=C1C(C1=NC=CC=C1C=1)=CC=1C1=CC=NC=C1 DRQNHAXZLIONQV-UHFFFAOYSA-N 0.000 claims 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
125000004429 atom Chemical group 0.000 claims 1
150000001875 compounds Chemical class 0.000 abstract description 46
208000006673 asthma Diseases 0.000 abstract description 17
239000003112 inhibitor Substances 0.000 abstract description 5
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract description 4
239000001257 hydrogen Substances 0.000 abstract description 4
229910052739 hydrogen Inorganic materials 0.000 abstract description 4
229940111121 antirheumatic drug quinolines Drugs 0.000 abstract description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
239000003795 chemical substances by application Substances 0.000 description 40
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 22
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 21
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 21
210000003979 eosinophil Anatomy 0.000 description 19
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 14
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 14
230000000694 effects Effects 0.000 description 14
239000002953 phosphate buffered saline Substances 0.000 description 14
108010044467 Isoenzymes Proteins 0.000 description 13
210000004027 cell Anatomy 0.000 description 13
239000000243 solution Substances 0.000 description 13
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
108060008682 Tumor Necrosis Factor Proteins 0.000 description 10
238000012360 testing method Methods 0.000 description 10
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 9
229940079593 drug Drugs 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
239000000203 mixture Substances 0.000 description 9
239000000047 product Substances 0.000 description 9
108091003079 Bovine Serum Albumin Proteins 0.000 description 8
206010006895 Cachexia Diseases 0.000 description 8
239000012894 fetal calf serum Substances 0.000 description 8
230000002401 inhibitory effect Effects 0.000 description 8
102000013585 Bombesin Human genes 0.000 description 7
108010051479 Bombesin Proteins 0.000 description 7
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
241000699670 Mus sp. Species 0.000 description 7
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
229960003638 dopamine Drugs 0.000 description 7
238000002844 melting Methods 0.000 description 7
230000008018 melting Effects 0.000 description 7
210000000440 neutrophil Anatomy 0.000 description 7
208000023504 respiratory system disease Diseases 0.000 description 7
239000000741 silica gel Substances 0.000 description 7
229910002027 silica gel Inorganic materials 0.000 description 7
PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 6
206010006482 Bronchospasm Diseases 0.000 description 6
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
206010040070 Septic Shock Diseases 0.000 description 6
238000003556 assay Methods 0.000 description 6
238000004949 mass spectrometry Methods 0.000 description 6
239000003921 oil Substances 0.000 description 6
150000003248 quinolines Chemical class 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 5
102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 5
230000004913 activation Effects 0.000 description 5
230000001363 autoimmune Effects 0.000 description 5
230000007885 bronchoconstriction Effects 0.000 description 5
210000005064 dopaminergic neuron Anatomy 0.000 description 5
238000010265 fast atom bombardment Methods 0.000 description 5
208000015122 neurodegenerative disease Diseases 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
230000036303 septic shock Effects 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
239000012981 Hank's balanced salt solution Substances 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
230000036428 airway hyperreactivity Effects 0.000 description 4
230000003110 anti-inflammatory effect Effects 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
206010006451 bronchitis Diseases 0.000 description 4
239000000872 buffer Substances 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
210000003743 erythrocyte Anatomy 0.000 description 4
210000002216 heart Anatomy 0.000 description 4
230000001506 immunosuppresive effect Effects 0.000 description 4
239000003018 immunosuppressive agent Substances 0.000 description 4
238000001802 infusion Methods 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
230000004770 neurodegeneration Effects 0.000 description 4
210000002569 neuron Anatomy 0.000 description 4
230000000241 respiratory effect Effects 0.000 description 4
229910052938 sodium sulfate Inorganic materials 0.000 description 4
235000011152 sodium sulphate Nutrition 0.000 description 4
239000000725 suspension Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
238000005160 1H NMR spectroscopy Methods 0.000 description 3
VRDZUYWMDMLDFG-UHFFFAOYSA-N 5-bromo-2-methylbenzotriazole Chemical compound C1=CC(Br)=CC2=NN(C)N=C21 VRDZUYWMDMLDFG-UHFFFAOYSA-N 0.000 description 3
208000030507 AIDS Diseases 0.000 description 3
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
208000035143 Bacterial infection Diseases 0.000 description 3
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
229930105110 Cyclosporin A Natural products 0.000 description 3
108010036949 Cyclosporine Proteins 0.000 description 3
206010014950 Eosinophilia Diseases 0.000 description 3
206010016654 Fibrosis Diseases 0.000 description 3
241000282412 Homo Species 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 3
229910000831 Steel Inorganic materials 0.000 description 3
SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 3
201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
230000000172 allergic effect Effects 0.000 description 3
239000002260 anti-inflammatory agent Substances 0.000 description 3
208000010668 atopic eczema Diseases 0.000 description 3
208000022362 bacterial infectious disease Diseases 0.000 description 3
230000036772 blood pressure Effects 0.000 description 3
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
229910052794 bromium Inorganic materials 0.000 description 3
230000007883 bronchodilation Effects 0.000 description 3
229940124630 bronchodilator Drugs 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
229960001265 ciclosporin Drugs 0.000 description 3
230000007882 cirrhosis Effects 0.000 description 3
208000019425 cirrhosis of liver Diseases 0.000 description 3
229940095074 cyclic amp Drugs 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
239000003480 eluent Substances 0.000 description 3
239000012458 free base Substances 0.000 description 3
229960003444 immunosuppressant agent Drugs 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
239000002245 particle Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
210000003491 skin Anatomy 0.000 description 3
238000000527 sonication Methods 0.000 description 3
239000010959 steel Substances 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
GJESTGYVLZKCIN-UHFFFAOYSA-N (2-methylbenzotriazol-5-yl)boronic acid Chemical compound C1=CC(B(O)O)=CC2=NN(C)N=C21 GJESTGYVLZKCIN-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
SLBDHCKWHDQGLS-UHFFFAOYSA-N 2-bromo-4-(pyridin-4-ylmethyl)aniline Chemical compound C1=C(Br)C(N)=CC=C1CC1=CC=NC=C1 SLBDHCKWHDQGLS-UHFFFAOYSA-N 0.000 description 2
FWWOWPGPERBCNJ-UHFFFAOYSA-N 2-hydroxy-4-(2-hydroxyethoxy)-4-oxobutanoic acid Chemical compound OCCOC(=O)CC(O)C(O)=O FWWOWPGPERBCNJ-UHFFFAOYSA-N 0.000 description 2
102000001707 3',5'-Cyclic-AMP Phosphodiesterases Human genes 0.000 description 2
108010054479 3',5'-Cyclic-AMP Phosphodiesterases Proteins 0.000 description 2
CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 2
JCTVZZVQCAVABY-UHFFFAOYSA-N 4-[3-methyl-6-(pyridin-4-ylmethyl)quinolin-8-yl]-2,1,3-benzoxadiazole Chemical compound C=1C2=CC(C)=CN=C2C(C=2C3=NON=C3C=CC=2)=CC=1CC1=CC=NC=C1 JCTVZZVQCAVABY-UHFFFAOYSA-N 0.000 description 2
RQYWTGPKZFPMDD-UHFFFAOYSA-N 4-[6-(pyridin-4-ylmethyl)quinolin-8-yl]-2,1,3-benzoxadiazole Chemical compound C=1C(C=2C3=NON=C3C=CC=2)=C2N=CC=CC2=CC=1CC1=CC=NC=C1 RQYWTGPKZFPMDD-UHFFFAOYSA-N 0.000 description 2
FXQKWDMHOOXMRV-UHFFFAOYSA-N 4-bromo-2,1,3-benzoxadiazole Chemical compound BrC1=CC=CC2=NON=C12 FXQKWDMHOOXMRV-UHFFFAOYSA-N 0.000 description 2
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 2
DYLQTXBMYHAOKZ-UHFFFAOYSA-N 8-bromo-3-methyl-6-(pyridin-4-ylmethyl)quinoline Chemical compound C=1C2=CC(C)=CN=C2C(Br)=CC=1CC1=CC=NC=C1 DYLQTXBMYHAOKZ-UHFFFAOYSA-N 0.000 description 2
UAVZJDMOBZQHKF-UHFFFAOYSA-N 8-bromo-6-(pyridin-4-ylmethyl)quinoline Chemical compound C=1C2=CC=CN=C2C(Br)=CC=1CC1=CC=NC=C1 UAVZJDMOBZQHKF-UHFFFAOYSA-N 0.000 description 2
HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical group C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
206010003645 Atopy Diseases 0.000 description 2
206010012289 Dementia Diseases 0.000 description 2
208000020401 Depressive disease Diseases 0.000 description 2
206010012438 Dermatitis atopic Diseases 0.000 description 2
206010012442 Dermatitis contact Diseases 0.000 description 2
208000031886 HIV Infections Diseases 0.000 description 2
208000037357 HIV infectious disease Diseases 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
208000022559 Inflammatory bowel disease Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
102000008109 Mixed Function Oxygenases Human genes 0.000 description 2
108010074633 Mixed Function Oxygenases Proteins 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 2
229930040373 Paraformaldehyde Natural products 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
229940124639 Selective inhibitor Drugs 0.000 description 2
206010039966 Senile dementia Diseases 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
239000012190 activator Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
150000001350 alkyl halides Chemical class 0.000 description 2
235000019270 ammonium chloride Nutrition 0.000 description 2
208000007502 anemia Diseases 0.000 description 2
229940121363 anti-inflammatory agent Drugs 0.000 description 2
229940124599 anti-inflammatory drug Drugs 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
201000008937 atopic dermatitis Diseases 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
210000000621 bronchi Anatomy 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
230000003920 cognitive function Effects 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
210000001653 corpus striatum Anatomy 0.000 description 2
229930182912 cyclosporin Natural products 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
230000028436 dopamine uptake Effects 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000002500 effect on skin Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000284 extract Substances 0.000 description 2
208000024711 extrinsic asthma Diseases 0.000 description 2
238000009472 formulation Methods 0.000 description 2
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
230000004968 inflammatory condition Effects 0.000 description 2
201000010659 intrinsic asthma Diseases 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000003120 macrolide antibiotic agent Substances 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
239000006249 magnetic particle Substances 0.000 description 2
210000001259 mesencephalon Anatomy 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
235000019796 monopotassium phosphate Nutrition 0.000 description 2
LGQLOGILCSXPEA-UHFFFAOYSA-L nickel sulfate Chemical compound [Ni+2].[O-]S([O-])(=O)=O LGQLOGILCSXPEA-UHFFFAOYSA-L 0.000 description 2
229910000363 nickel(II) sulfate Inorganic materials 0.000 description 2
239000006186 oral dosage form Substances 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052763 palladium Inorganic materials 0.000 description 2
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
229920002866 paraformaldehyde Polymers 0.000 description 2
150000002978 peroxides Chemical class 0.000 description 2
PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
206010035653 pneumoconiosis Diseases 0.000 description 2
239000001103 potassium chloride Substances 0.000 description 2
235000011164 potassium chloride Nutrition 0.000 description 2
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000010992 reflux Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
206010039083 rhinitis Diseases 0.000 description 2
239000013049 sediment Substances 0.000 description 2
238000000926 separation method Methods 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
208000017520 skin disease Diseases 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
210000003437 trachea Anatomy 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 2
VHNILDKAFINLSQ-UHFFFAOYSA-N 1-[3-(aminomethyl)-4-(4-methylphenyl)-2-(2-methylpropyl)quinolin-6-yl]piperazine-2,5-dione Chemical compound NCC=1C(CC(C)C)=NC2=CC=C(N3C(CNC(=O)C3)=O)C=C2C=1C1=CC=C(C)C=C1 VHNILDKAFINLSQ-UHFFFAOYSA-N 0.000 description 1
VDCLCAXYTCLVQY-CTVGSUQISA-N 2-[(3s,6s,9s,15s,18s,21s,24s,27s)-15,18-di(butan-2-yl)-6-[(4-methoxyphenyl)methyl]-3,10,16,19,22,28-hexamethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-9,24,27-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28-decazabicyclo[28.4.0]tetratriacontan-21-yl]acetic acid Chemical compound C([C@H]1C(=O)N[C@@H](C)C(=O)N2CCCCC2C(=O)N(C)[C@@H](C(C)C)C(=O)N[C@H](C(=O)N(C)[C@@H](CC(O)=O)C(=O)N(C)[C@@H](C(C)CC)C(=O)N(C)[C@H](C(NCC(=O)N(C)[C@@H](C(C)C)C(=O)N1)=O)C(C)CC)C(C)C)C1=CC=C(OC)C=C1 VDCLCAXYTCLVQY-CTVGSUQISA-N 0.000 description 1
MBOVZBKVDAMSEZ-UHFFFAOYSA-N 2-methylbenzotriazol-5-amine Chemical compound C1=CC(N)=CC2=NN(C)N=C21 MBOVZBKVDAMSEZ-UHFFFAOYSA-N 0.000 description 1
PWORFEDVDWBHSJ-UHFFFAOYSA-N 2-methylbenzotriazole Chemical compound C1=CC=CC2=NN(C)N=C21 PWORFEDVDWBHSJ-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
TZHOXMIBHQSBTN-UHFFFAOYSA-N 3-bromo-1h-2,1,3-benzoxadiazole Chemical compound C1=CC=C2N(Br)ONC2=C1 TZHOXMIBHQSBTN-UHFFFAOYSA-N 0.000 description 1
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
GZWZLWDQRWMBCE-UHFFFAOYSA-N 8-bromo-6-(4-methylpyridin-2-yl)quinoline Chemical compound CC1=CC=NC(C=2C=C3C=CC=NC3=C(Br)C=2)=C1 GZWZLWDQRWMBCE-UHFFFAOYSA-N 0.000 description 1
229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
208000000884 Airway Obstruction Diseases 0.000 description 1
206010001889 Alveolitis Diseases 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
208000033116 Asbestos intoxication Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
206010003557 Asthma exercise induced Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
206010006473 Bronchopulmonary aspergillosis Diseases 0.000 description 1
208000007596 Byssinosis Diseases 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
102000000584 Calmodulin Human genes 0.000 description 1
108010041952 Calmodulin Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
206010008469 Chest discomfort Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
206010010305 Confusional state Diseases 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
108010069514 Cyclic Peptides Proteins 0.000 description 1
102000001189 Cyclic Peptides Human genes 0.000 description 1
FMGYKKMPNATWHP-UHFFFAOYSA-N Cyperquat Chemical compound C1=C[N+](C)=CC=C1C1=CC=CC=C1 FMGYKKMPNATWHP-UHFFFAOYSA-N 0.000 description 1
206010048768 Dermatosis Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
206010060742 Endocrine ophthalmopathy Diseases 0.000 description 1
206010014824 Endotoxic shock Diseases 0.000 description 1
241000792859 Enema Species 0.000 description 1
208000004657 Exercise-Induced Asthma Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
208000003807 Graves Disease Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
238000007341 Heck reaction Methods 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
208000029523 Interstitial Lung disease Diseases 0.000 description 1
208000004883 Lipoid Nephrosis Diseases 0.000 description 1
201000009324 Loeffler syndrome Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
STNJBCKSHOAVAJ-UHFFFAOYSA-N Methacrolein Chemical compound CC(=C)C=O STNJBCKSHOAVAJ-UHFFFAOYSA-N 0.000 description 1
208000026072 Motor neurone disease Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
125000004633 N-oxo-pyridyl group Chemical group 0.000 description 1
238000006411 Negishi coupling reaction Methods 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
208000027771 Obstructive airways disease Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
241000721454 Pemphigus Species 0.000 description 1
108700020962 Peroxidase Proteins 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
206010065159 Polychondritis Diseases 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
208000004430 Pulmonary Aspergillosis Diseases 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
238000000297 Sandmeyer reaction Methods 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
201000010001 Silicosis Diseases 0.000 description 1
238000005614 Skraup synthesis reaction Methods 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
241000272534 Struthio camelus Species 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
238000006069 Suzuki reaction reaction Methods 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
206010065258 Tropical eosinophilia Diseases 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
206010047924 Wheezing Diseases 0.000 description 1
208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 1
NJEWSEBWTPCOJN-UHFFFAOYSA-N [Ni].NNC1=CC=C(C2=CC=C(NN)C=C2)C=C1 Chemical compound [Ni].NNC1=CC=C(C2=CC=C(NN)C=C2)C=C1 NJEWSEBWTPCOJN-UHFFFAOYSA-N 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
208000002205 allergic conjunctivitis Diseases 0.000 description 1
208000002029 allergic contact dermatitis Diseases 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
208000028462 aluminosis Diseases 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000001088 anti-asthma Effects 0.000 description 1
239000000924 antiasthmatic agent Substances 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000006286 aqueous extract Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
206010003441 asbestosis Diseases 0.000 description 1
ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 description 1
ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
229940125388 beta agonist Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000009530 blood pressure measurement Methods 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
239000012267 brine Substances 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
230000000572 bronchospasmolytic effect Effects 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000000451 chemical ionisation Methods 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
230000006999 cognitive decline Effects 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
238000011262 co‐therapy Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000037029 cross reaction Effects 0.000 description 1
239000010779 crude oil Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
239000002577 cryoprotective agent Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
230000009429 distress Effects 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
229940112141 dry powder inhaler Drugs 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 1
238000000605 extraction Methods 0.000 description 1
201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
201000005298 gastrointestinal allergy Diseases 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
238000011597 hartley guinea pig Methods 0.000 description 1
208000014951 hematologic disease Diseases 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
230000003463 hyperproliferative effect Effects 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
208000013397 idiopathic acute eosinophilic pneumonia Diseases 0.000 description 1
208000016036 idiopathic nephrotic syndrome Diseases 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
229940124589 immunosuppressive drug Drugs 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
201000010666 keratoconjunctivitis Diseases 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
KNJDBYZZKAZQNG-UHFFFAOYSA-N lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
210000002161 motor neuron Anatomy 0.000 description 1
208000005264 motor neuron disease Diseases 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000007171 neuropathology Effects 0.000 description 1
239000002581 neurotoxin Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
230000002474 noradrenergic effect Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
208000007892 occupational asthma Diseases 0.000 description 1
239000002674 ointment Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000000162 organ preservation solution Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
238000006053 organic reaction Methods 0.000 description 1
125000002524 organometallic group Chemical group 0.000 description 1
150000003891 oxalate salts Chemical class 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
229960001789 papaverine Drugs 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
108010091212 pepstatin Proteins 0.000 description 1
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
WRLGYAWRGXKSKG-UHFFFAOYSA-M phenobarbital sodium Chemical compound [Na+].C=1C=CC=CC=1C1(CC)C(=O)NC([O-])=NC1=O WRLGYAWRGXKSKG-UHFFFAOYSA-M 0.000 description 1
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 1
239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
235000015497 potassium bicarbonate Nutrition 0.000 description 1
229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
239000011736 potassium bicarbonate Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
210000004879 pulmonary tissue Anatomy 0.000 description 1
125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000000552 rheumatic effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
210000001044 sensory neuron Anatomy 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
230000002295 serotoninergic effect Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
208000004003 siderosis Diseases 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
229960002930 sirolimus Drugs 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000002636 symptomatic treatment Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
XWNXEWLCHSLQOI-UHFFFAOYSA-K trisodium;triacetate Chemical compound [Na+].[Na+].[Na+].CC([O-])=O.CC([O-])=O.CC([O-])=O XWNXEWLCHSLQOI-UHFFFAOYSA-K 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
229910052720 vanadium Inorganic materials 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000009423 ventilation Methods 0.000 description 1
208000018464 vernal keratoconjunctivitis Diseases 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Immunology (AREA)
Psychology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

SK639-98A 1995-11-14 1996-11-13 Quinoline derivatives, method for the preparation thereof, pharmaceutical composition containing same, and their use SK63998A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9523267.4A GB9523267D0 (en)	1995-11-14	1995-11-14	Organic compounds
PCT/EP1996/004978 WO1997018208A1 (en)	1995-11-14	1996-11-13	Quinoline derivatives as type iv phosphodiesterase inhibitors

Publications (1)

Publication Number	Publication Date
SK63998A3 true SK63998A3 (en)	1998-10-07

Family

ID=10783856

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK639-98A SK63998A3 (en)	1995-11-14	1996-11-13	Quinoline derivatives, method for the preparation thereof, pharmaceutical composition containing same, and their use

Country Status (17)

Country	Link
EP (1)	EP0873338A1 (cs)
JP (1)	JPH11515000A (cs)
KR (1)	KR19990067574A (cs)
CN (1)	CN1202170A (cs)
AU (1)	AU7570996A (cs)
BR (1)	BR9611504A (cs)
CA (1)	CA2235126A1 (cs)
CO (1)	CO4770973A1 (cs)
CZ (1)	CZ149498A3 (cs)
GB (1)	GB9523267D0 (cs)
HU (1)	HUP9903492A3 (cs)
MX (1)	MX9803839A (cs)
PE (1)	PE17598A1 (cs)
PL (1)	PL326636A1 (cs)
SK (1)	SK63998A3 (cs)
TR (1)	TR199800851T2 (cs)
WO (1)	WO1997018208A1 (cs)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL200923B1 (pl)	1999-08-21	2009-02-27	Nycomed Gmbh	Lek zawierający inhibitor PDE w połączeniu z agonistą receptoraß₂ -adrenergicznego oraz zastosowanie połączenia roflumilastu i salmeterolu
KR20040007583A (ko)	2001-05-23	2004-01-24	다나베 세이야꾸 가부시키가이샤	연골 질환의 재생치료용 조성물
WO2002094321A1 (en)	2001-05-23	2002-11-28	Tanabe Seiyaku Co., Ltd.	Compositions for promoting healing of bone fracture
JP2006522151A (ja)	2003-04-01	2006-09-28	アプライドリサーチシステムズエーアールエスホールディングナームロゼフェンノートシャップ	不妊症におけるホスホジエステラーゼ阻害剤
WO2005070891A2 (en) *	2004-01-23	2005-08-04	Amgen Inc	Compounds and methods of use
JP2006347936A (ja) *	2005-06-15	2006-12-28	Bayer Cropscience Ag	殺虫性ベンズアニリド類
US8394829B2 (en)	2010-05-10	2013-03-12	Gilead Sciences, Inc.	Bi-functional quinoline analogs
WO2011143106A1 (en)	2010-05-10	2011-11-17	Gilead Sciences, Inc.	Bi - functional pyrazolopyridine compounds
WO2014062655A1 (en)	2012-10-16	2014-04-24	Janssen Pharmaceutica Nv	HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt
MY189505A (en)	2012-10-16	2022-02-16	Janssen Pharmaceutica Nv	Methylene linked quinolinyl modulators of roryt
HK1213887A1 (zh)	2012-10-16	2016-07-15	Janssen Pharmaceutica N.V.	RORγt的苯基连接的喹啉基调节剂
US10555941B2 (en)	2013-10-15	2020-02-11	Janssen Pharmaceutica Nv	Alkyl linked quinolinyl modulators of RORγt
US9403816B2 (en)	2013-10-15	2016-08-02	Janssen Pharmaceutica Nv	Phenyl linked quinolinyl modulators of RORγt
CA2927182A1 (en)	2013-10-15	2015-04-23	Janssen Pharmaceutica Nv	Quinolinyl modulators of ror.gamma.t
US9284308B2 (en)	2013-10-15	2016-03-15	Janssen Pharmaceutica Nv	Methylene linked quinolinyl modulators of RORγt
CA2926339A1 (en)	2013-10-15	2015-04-23	Janssen Pharmaceutica Nv	Alkyl linked quinolinyl modulators of roryt
US9221804B2 (en)	2013-10-15	2015-12-29	Janssen Pharmaceutica Nv	Secondary alcohol quinolinyl modulators of RORγt
US9328095B2 (en)	2013-10-15	2016-05-03	Janssen Pharmaceutica Nv	Heteroaryl linked quinolinyl modulators of RORgammat
US11427545B2 (en) *	2018-06-24	2022-08-30	Adama Agan Ltd.	Process for the preparation of Quinmerac

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9027055D0 (en) *	1990-12-13	1991-02-06	Sandoz Ltd	Organic compounds
US5455252A (en) *	1993-03-31	1995-10-03	Syntex (U.S.A.) Inc.	Optionally substituted 6,8-quinolines

1995
- 1995-11-14 GB GBGB9523267.4A patent/GB9523267D0/en active Pending
1996
- 1996-11-12 PE PE1996000810A patent/PE17598A1/es not_active Application Discontinuation
- 1996-11-13 SK SK639-98A patent/SK63998A3/sk unknown
- 1996-11-13 CN CN96198305A patent/CN1202170A/zh active Pending
- 1996-11-13 AU AU75709/96A patent/AU7570996A/en not_active Abandoned
- 1996-11-13 JP JP9515313A patent/JPH11515000A/ja not_active Withdrawn
- 1996-11-13 EP EP96938196A patent/EP0873338A1/en not_active Withdrawn
- 1996-11-13 CA CA002235126A patent/CA2235126A1/en not_active Abandoned
- 1996-11-13 TR TR1998/00851T patent/TR199800851T2/xx unknown
- 1996-11-13 WO PCT/EP1996/004978 patent/WO1997018208A1/en not_active Ceased
- 1996-11-13 CZ CZ981494A patent/CZ149498A3/cs unknown
- 1996-11-13 KR KR1019980703597A patent/KR19990067574A/ko not_active Withdrawn
- 1996-11-13 HU HU9903492A patent/HUP9903492A3/hu unknown
- 1996-11-13 BR BR9611504A patent/BR9611504A/pt not_active Application Discontinuation
- 1996-11-13 CO CO96059775A patent/CO4770973A1/es unknown
- 1996-11-13 PL PL96326636A patent/PL326636A1/xx unknown
1998
- 1998-05-14 MX MX9803839A patent/MX9803839A/es unknown

Also Published As

Publication number	Publication date
WO1997018208A1 (en)	1997-05-22
KR19990067574A (ko)	1999-08-25
EP0873338A1 (en)	1998-10-28
CN1202170A (zh)	1998-12-16
HUP9903492A2 (en)	2000-07-28
CA2235126A1 (en)	1997-05-22
BR9611504A (pt)	1999-03-02
TR199800851T2 (xx)	1998-08-21
JPH11515000A (ja)	1999-12-21
GB9523267D0 (en)	1996-01-17
CO4770973A1 (es)	1999-04-30
AU7570996A (en)	1997-06-05
PL326636A1 (en)	1998-10-12
MX9803839A (es)	1998-09-30
CZ149498A3 (cs)	1998-08-12
PE17598A1 (es)	1998-04-06
HUP9903492A3 (en)	2000-08-28

Publication	Publication Date	Title
CZ149498A3 (cs)	1998-08-12	Deriváty chinolinu, způsob jejich přípravy, farmaceutický prostředek, který je obsahuje, a jejich použití
US5177085A (en)	1993-01-05	Dihydro-isoquinoline derivatives, processes for their production, pharmaceutical compositions containing them, and their use in treating asthma
US5747506A (en)	1998-05-05	Isoquinoline compounds, compositions containing them and their pharmaceutical uses
US6136821A (en)	2000-10-24	Naphthyridine derivatives
KR100484045B1 (ko)	2005-04-20	기관지 치료용 벤조나프티리딘
US4980359A (en)	1990-12-25	Isoquinoline derivatives and their use
KR20070043968A (ko)	2007-04-26	Ｐａｒｐ 저해제로서의 치환 ２-알킬 퀴나졸리논 유도체
EP1332147A1 (en)	2003-08-06	Thieno[2,3-c isoquinolines for use as inhibitors of parp
JPWO1997019078A1 (ja)	1998-12-22	ピリド［２，３−ｄ］ピリミジン誘導体及びその医薬組成物
JP2006506414A (ja)	2006-02-23	抗炎症性３−アリールチオ−３−チアゾリル−アルキルアミン
EP1142881A1 (en)	2001-10-10	Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives
SU1395140A3 (ru)	1988-05-07	Способ получени карбостирильных производных
SK170299A3 (en)	2000-08-14	Aminospiro piperidine quinazoline derivatives, process and intermediates to their preparation, pharmaceutical compositions them containing and their use
JP2007507463A (ja)	2007-03-29	誘導性ＮＯシンターゼ阻害剤としてのイミダゾ［４，５−ｂ］ピリジン誘導体
US20200361902A1 (en)	2020-11-19	Crystal form i of a 5-aminopyrazole carboxamide compound as btk inhibitor
NO178430B (no)	1995-12-18	Nye dihydroisokinolinderivater og deres anvendelse som terapeutikum
HK1022305B (en)	2004-02-06	Naphthyridine derivatives